R&D channel feed

Bris­tol My­ers builds the case for pso­ri­a­sis hope­ful as it waits in reg­u­la­to­ry lim­bo

4 years ago
Pharma

A week af­ter dis­clos­ing lay­offs, Bridge­Bio nets a $90M up­front can­cer R&D pact with Bris­tol My­ers

4 years ago
Deals
Pharma

Take­da boots a top prospect out of its late-stage pipeline while an­oth­er is de­layed by war, lock­down

4 years ago

The col­lapse of SKY­SCRAPER-01 is cast­ing a pall over all the TIG­ITs. Are we in for an­oth­er I/O fi­as­co?

4 years ago
Bioregnum

Iterum says FDA is in 'gen­er­al align­men­t' on pro­posed new PhI­II for re­ject­ed uU­TI drug

4 years ago

As­traZeneca and Sanofi sharp­en RSV pitch with new analy­ses, but how much weight will FDA give them?

4 years ago

Roche goes 0-2 in the high-stakes race to get a TIG­IT through PhI­II and on­to the mar­ket

4 years ago

Scoop: Green Val­ley's sea­weed-de­rived Alzheimer's drug, ap­proved in Chi­na, is halt­ed in PhI­II study

4 years ago
China
Pharma

Just months af­ter its first FDA ap­proval, Idor­sia dumps binge-eat­ing drug can­di­date af­ter PhII fail

4 years ago

Verve gets New Zealand clear­ance to test base edit­ing ther­a­py di­rect­ly in the hu­man body

4 years ago
Cell/Gene Tx

Fi­bro­Gen CEO: Roxa path blocked as As­traZeneca re­mains un­de­cid­ed on just what it plans to do in the wake of a CRL

4 years ago
Pharma

Bio­gen piv­ots to sec­ond amy­loid-tar­get­ed Alzheimer's drug with ac­cel­er­at­ed ap­proval fil­ing from part­ner Ei­sai

4 years ago
FDA+

An­oth­er TIG­IT up­date from Ar­cus leaves an­a­lysts read­ing the tea leaves — and the big re­veal is fi­nal­ly near

4 years ago

Ex­clu­sive: No­vo Nordisk al­lies it­self with one of the buzzi­est groups in biotech, launch­ing a mul­ti-pronged at­tack at dis­cov­er­ing new drugs

4 years ago
Deals

Scoop: Ex­e­Vir hits pause on lla­ma-de­rived Covid an­ti­body amid Omi­cron vari­ants, shifts fo­cus to sec­ond-gen work

4 years ago
Startups
Coronavirus

Bel­gian eye biotech gets ham­mered by in­vestors af­ter PhII tri­al fails ef­fi­ca­cy on key end­points

4 years ago

In wake of do­mes­tic vi­o­lence al­le­ga­tion, long­time Seagen CEO Clay Sie­gall goes on leave

4 years ago
People

Af­ter last mon­th's ad­comm death knell on its ALS drug, Amy­lyx looks to post-hoc for sav­ing grace

4 years ago
Pharma

As­traZeneca's Ul­tomiris hits pri­ma­ry end­point for PhI­II NMOSD study

4 years ago
Pharma

BioCryst of­fi­cial­ly gets par­tial clin­i­cal hold on lead can­di­date af­ter halt­ing en­roll­ment

4 years ago
FDA+

Con­gress mulls soft­er ac­cel­er­at­ed ap­proval re­forms as part of user fee reau­tho­riza­tions

4 years ago

A virus may have dri­ven the death of the first pa­tient to re­ceive a ge­net­i­cal­ly mod­i­fied pig heart

4 years ago

As­traZeneca adds a ma­jor PhI­II win for Farx­i­ga, set­ting up an­oth­er bat­tle­front with Big Phar­ma ri­vals

4 years ago

No­var­tis' com­pas­sion­ate use re­quests world­wide: Just 0.5% came from low­er-mid­dle- and low-in­come coun­tries

4 years ago
Pharma
First page Previous page 136137138139140141142 Next page Last page
A service from the Financial Times